Drug Profile
SNP 630
Alternative Names: SNP-630Latest Information Update: 17 Aug 2023
Price :
$50
*
At a glance
- Originator Sinew Pharma
- Class Drug conjugates; Hepatoprotectants; Immunoconjugates
- Mechanism of Action Cytochrome P 450 enzyme system inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-alcoholic steatohepatitis
Most Recent Events
- 21 Jun 2023 Pharmacodynamics data from a preclinical studies in Non alcoholic steatohepatitis presented at the European Association for the Study of the Liver Congress 2023 (EASL-2023)
- 15 Jun 2023 Sinew Pharma plans a phase II trial for Non-alcoholic-steatohepatitis in Taiwan(PO) (Sinew Pharma pipeline, June 2023)
- 31 Aug 2021 Sinew Pharma completed a phase I trial in Non-alcoholic steatohepatitis (In volunteers) in Taiwan (PO) (NCT04808154)